Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors

• Published in: Gynecologic oncology Vol. 112; no. 2; pp. 394 - 399
• Main Authors: Matulonis, Ursula A, Krag, Karen J, Krasner, Carolyn N, Atkinson, Tina, Horowitz, Neil S, Lee, Hang, Penson, Richard T
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2009
• Subjects: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carboplatin - administration & dosage; Carboplatin - adverse effects; Chemotherapy; Combined Modality Therapy; Disease-Free Survival; Elderly; Endometrial Neoplasms - drug therapy; Endometrial Neoplasms - surgery; Fallopian Tube Neoplasms - drug therapy; Fallopian Tube Neoplasms - surgery; Female; Genital Neoplasms, Female - drug therapy; Genital Neoplasms, Female - surgery; Hematology, Oncology and Palliative Medicine; Humans; Mixed Tumor, Mullerian - drug therapy; Mixed Tumor, Mullerian - surgery; Obstetrics and Gynecology; Older patients; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - surgery; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Peritoneal Neoplasms - drug therapy; Peritoneal Neoplasms - surgery; Prospective Studies; Quality of Life; Older patients; Chemotherapy; Elderly; Ovarian cancer

Abstract Objectives The primary objective was to determine the completion rate of 6 cycles of paclitaxel and carboplatin chemotherapy with no dose reductions in patients ≥ 70 years of age. Methods Phase II study of intravenous (IV) carboplatin Area Under the Curve (AUC) of 5 and paclitaxel 175 mg/m2...